EMulate Therapeutics

Revolutionary Transformation of Medicine with BioElectromagnetic Technology

Imagine a world where cancer patients, such as children with brain tumors, could receive life-saving treatment without toxic chemotherapy. Where chronic pain sufferers could find relief without addictive opioids. Where mental health conditions could be managed with no significant observed side effects. This isn't science fiction, this is happening now at EMulate Therapeutics.

EMulate has solved one of medicine's most elusive challenges: delivering therapeutic benefits without physical drugs. Here's how it works in simple terms:

Every molecule, including medicines, creates unique electromagnetic "fingerprints" as it moves. Think of it like each drug having its own song. EMulate's scientists use ultra-sensitive equipment to record these molecular songs, then play them back to patients using safe, low-energy radio waves through a simple wearable device.

The result? Your body responds as if it received the actual medication, but without any chemicals entering your system. No toxicity. No observed significant side effects. Just therapeutic benefits.

ulRFE® Technology 

A proprietary mechanism for the non-toxic, non-invasive, non-ionizing and effective treatment of cancer, pain, mental health and general wellness.

Pediatric Brain Cancer: A Breakthrough Where None Existed

EMulate's most advanced program targets Diffuse Midline Glioma (DMG), including Diffuse Intrinsic Pontine Glioma (DIPG), devastating childhood brain cancers that have seen no meaningful treatment advances in decades.

The Drug They Emulate: Paclitaxel (Taxol), a powerful chemotherapy drug that works by disrupting cancer cell division. While highly effective against many cancers, paclitaxel cannot cross the blood-brain barrier, making it useless for brain tumors until now.

The science behind this success: EMulate's “song” of paclitaxel, like the drug itself, promotes tubulin polymerization (the process that slows cancer cell division), but delivers this effect directly to brain tumors, unlike drugs, which would need to (but cannot) cross the blood-brain barrier. 

Adult Brain Cancer (Glioblastoma): First Real Progress in Decades

For glioblastoma multiforme (GBM), the most common and aggressive adult brain cancer, EMulate's Voyager system has shown remarkable result

Expanding Oncology Applications

Beyond brain cancers, EMulate has demonstrated responses in over 20 different tumor types through veterinary canine studies, including:

• Complete responses in osteosarcoma, lymphomas, and carcinomas
• Partial responses in melanoma, fibrosarcoma, and mammary tumors
• Over 300 pets treated with naturally occurring cancers
• Responses observed as early as 14 days with therapy

  

Revolutionizing Psychiatric Treatment

EMulate's mental health program leverages the therapeutic potential of psychedelic compounds while reducing or eliminating many risks and drug-related challenges. The company has successfully emulated the effects of several breakthrough mental health medications.

The Drugs They Emulate:

• DOI (2,5-Dimethoxy-4-iodoamphetamine): A research psychedelic used as the "gold standard" in psychiatric studies
• Ketamine: FDA-approved for treatment-resistant depression
• MDMA: which is currently in Phase 3 trials for PTSD
• Psilocybin: Breakthrough therapy designation for depression
• CBD and THC: in active research for depression and anxiety

  

  

  

Breaking the Addiction Cycle

With the opioid crisis claiming over 100,000 lives annually in the US alone, EMulate's pain management platform offers hope for non-addictive, effective pain relief.

The Drugs We Emulate:

• Fentanyl: The most powerful opioid painkiller
• CBD (Cannabidiol): Natural anti-inflammatory compound
• NSAIDs: Including naproxen and indomethacin
• Hydromorphone: Another potent opioid

Inflammatory Pain Model:

• Fentanyl signal: 65% pain reduction (p≤0.01)
• CBD signal: 65% pain reduction (p≤0.01)
• Both outperformed indomethacin (standard anti-inflammatory)

Neuropathic Pain Model:

• Fentanyl signal: 82% pain reduction (p≤0.01)
• CBD signal: 70% pain reduction (p≤0.01)
• Naproxen signal: 79% pain reduction (p≤0.01)

Post-Surgical Pain Model:

• Fentanyl signal: 70% pain reduction (p=0.01)
• Comparable to high-dose morphine without addiction risk

Human Case Studies:

Five military veterans with chronic pain conditions treated at a VA medical center:

• 38% average reduction in pain scores (Visual Analog Scale)
• Pain scores dropped from 8/10 to 5/10 average
• Effects observed within 15-30 minutes
• All patients had previously failed traditional pain management

EMulate's pain device combines signals from opioids, NSAIDs, and CBD to create multi-modal pain relief potentially without:

• Addiction
• Liver toxicity
• Gastrointestinal side effects
• Respiratory depression
• Drug interactions

  

How BioElectromagnetic Technology Works

EMulate's technology operates on fundamental principles of biophysics. Non-covalent molecular interactions, the same forces that allow drugs to produce a biological response, involve electromagnetic fields. With these fields, EMulate triggers the same biological cascades as physical drugs.

Safety Profile Across All Programs

With over 165 human patients treated across oncology trials, millions of hours of consumer exposure through Hapbee, and extensive animal testing:

• Zero serious adverse events attributable to ulRFE technology
• No thermal effects (non-heating)
• No ionizing radiation (low energy levels)
• No observed tissue damage or cellular toxicity

  

This isn't just about one disease. EMulate's platform can theoretically recreate the effects of any non-covalent drug molecule. 

Our patented ultra-low radio frequency energy (ulRFE®) technology records and reproduces specific electromagnetic patterns associated with familiar compounds, then plays those patterns through lightweight wearables for consumers. The result is an on-demand, drug-free way to nudge sleep, focus, calm, or energy with instant on/off control drug-free.

The Hapbee Neckband targets daytime performance (Focus, Energy, Calm, Relax) while the Hapbee Sleep Pad lives under your pillow for nighttime use (Deep Sleep, Wind Down, Wake Up). Both pair to an app with a growing library of “signal blends,” letting users choose how they want to feel throughout the day and night. 

Led by CEO Chris Rivera, who previously built and sold Hyperion Therapeutics for $1.1 billion, EMulate's team combines decades of biotech success with cutting-edge scientific innovation. The board includes veterans from Microsoft, Bristol Myers Squibb, and multiple successful biotech ventures.

Near-Term Revenue Catalysts

• 2027: Projected commercial launch for pediatric brain cancer (DMG/DIPG)
• $100M+ market opportunity within 3 years of launch (not guaranteed)
• Multiple Phase 1 trials starting in 2025 for pain and mental health 
• Ongoing License royalties from Hapbee Technologies

Massive Market Potential

• Brain Cancer: $4.8B by 2030
• Mental Health: $567B by 2032
• Pain Management: $114B by 2032
• Total addressable market exceeds $700 billion

Proven Business Model

• Revenues through licensing deals with Teijin Pharma (Japan) and Sayre Therapeutics (India)
• 15 issued patents protecting the technology
• Hapbee already commercializing consumer wearable products

Capital Efficiency

Unlike traditional drug development requiring billions in investment:

• New treatments developed in less than 12 months
• Under $500,000 from concept to clinical readiness
• No need to invent new molecules, just record existing ones